science
Federal Judge Denies Block on Mail-Order Abortion Pill but Orders FDA Review Completion
A U.S. federal judge in Louisiana ruled on Tuesday that the Food and Drug Administration must complete its review of mifepristone mailing restrictions, denying a preliminary block for now. The decision maintains national access to the abortion pill via mail and telehealth temporarily. The ruling stems from a lawsuit challenging FDA policies on the drug used in medication abortions.
ST
NPRAudio version
Tap play to generate a narrated version.
A federal judge in the Western District of Louisiana ruled on Tuesday that access to mifepristone, a drug used in medication abortions, remains unchanged nationally for the time being. The decision denies a request to immediately block the FDA's policy allowing the pill to be sent by mail and obtained through telehealth. Judge David C.
Joseph issued a 37-page opinion emphasizing that the FDA must finish its ongoing review of the policy. The lawsuit was filed by plaintiffs seeking to restrict mifepristone distribution, arguing that mailing the drug poses safety risks. Judge Joseph found insufficient evidence at this stage to halt the current access methods.
The ruling applies nationwide, preserving telehealth abortion options amid ongoing legal challenges.
his opinion, Judge Joseph stated that the FDA's review process, initiated in response to prior litigation, requires completion before any changes can be imposed.
The judge rejected the plaintiffs' motion for a preliminary injunction, noting that the agency's evaluation addresses the core concerns raised. This decision follows a series of court battles over mifepristone since its approval decades ago. The FDA approved mifepristone in 2000 for use in combination with misoprostol to terminate pregnancies up to 10 weeks gestation.
Recent lawsuits have targeted expansions in access, including mail delivery approved in 2021 during the COVID-19 pandemic. Judge Joseph's order mandates the FDA to finalize its review within specified timelines, though exact dates were not detailed in available reports.
abortions have increased significantly since 2020, with mifepristone accounting for over half of U.S. abortions. The ruling comes after the Supreme Court's 2024 decision upholding FDA authority on the drug's approval, but it leaves room for further restrictions pending the review.
